We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
-6.57%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$992B
AUM Growth
-$120B
Cap. Flow
-$16.9B
Cap. Flow %
-1.7%
Top 10 Hldgs %
27.94%
Holding
3,085
New
108
Increased
1,637
Reduced
1,059
Closed
107

Top Buys

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$4.45B
2
JPM icon
JPMorgan Chase
JPM
+$2.22B
3
TEAM icon
Atlassian
TEAM
+$2.08B
4
NVDA icon
NVIDIA
NVDA
+$1.81B
5
AAPL icon
Apple
AAPL
+$1.67B

Sector Composition

Rank Sector Weight
1 Technology 26.79%
2 Healthcare 17.19%
3 Consumer Discretionary 15.16%
4 Financials 10.74%
5 Communication Services 10.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ALR
2926
DELISTED
AlerisLife Inc
ALR
$37K ﹤0.01%
17,400
STEX
2927
Streamex Corp
STEX
$87.3M
$35K ﹤0.01%
3,020
-1,640
-35% -$26.2K
ENVB icon
2928
Enveric Biosciences
ENVB
$6.24M
$35K ﹤0.01%
12
-3
-20% -$13.3K
TIO
2929
DELISTED
Tingo Group, Inc. Common Stock
TIO
$34K ﹤0.01%
55,400
+31,100
+128% +$21.3K
DFTX
2930
Definium Therapeutics
DFTX
$5.75B
$33K ﹤0.01%
1,966
+434
+28% +$7.53K
KPRX icon
2931
Kiora Pharmaceuticals
KPRX
$11.7M
$32K ﹤0.01%
143
NAT icon
2932
Nordic American Tanker
NAT
$1.36B
$32K ﹤0.01%
15,064
+3,996
+36% +$7.09K
AFI
2933
DELISTED
Armstrong Flooring, Inc.
AFI
$32K ﹤0.01%
22,600
EMAN
2934
DELISTED
eMagin Corporation
EMAN
$31K ﹤0.01%
27,300
LPTH icon
2935
Lightpath Technologies
LPTH
$862M
$30K ﹤0.01%
15,300
AUD
2936
DELISTED
Audacy, Inc.
AUD
$30K ﹤0.01%
+10,513
New +$27.8K
CBUS icon
2937
Cibus
CBUS
$144M
$29K ﹤0.01%
562
SVRA icon
2938
Savara
SVRA
$1.17B
$29K ﹤0.01%
21,860
+4,600
+27% +$5.54K
RLX icon
2939
RLX Technology
RLX
$2.47B
$28K ﹤0.01%
15,500
URG
2940
Ur-Energy
URG
$537M
$26K ﹤0.01%
16,485
+4,500
+38% +$6.37K
CRBP icon
2941
Corbus Pharmaceuticals
CRBP
$189M
$25K ﹤0.01%
1,547
+553
+56% +$7.33K
RNAC icon
2942
Cartesian Therapeutics
RNAC
$263M
$21K ﹤0.01%
578
+113
+24% +$7.07K
VSTM icon
2943
Verastem
VSTM
$629M
$21K ﹤0.01%
1,260
+308
+32% +$5.3K
HAACW
2944
DELISTED
Health Assurance Acquisition Corp. Warrants
HAACW
$18K ﹤0.01%
35,000
BOAC.WS
2945
DELISTED
Bluescape Opportunities Acquisition Corp. Redeemable warrants, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
BOAC.WS
$16K ﹤0.01%
46,500
GOCO
2946
DELISTED
GoHealth
GOCO
$14K ﹤0.01%
775
-13,418
-95% -$418K
ONYXW
2947
DELISTED
Onyx Acquisition Co. I Warrant
ONYXW
$13K ﹤0.01%
+37,750
New +$13K
NMTR
2948
DELISTED
9 Meters Biopharma
NMTR
$12K ﹤0.01%
990
+274
+38% +$3.74K
GVCIW
2949
DELISTED
Green Visor Financial Technology Acquisition Corp. I Warrants
GVCIW
$12K ﹤0.01%
+37,925
New +$16K
TNXP icon
2950
Tonix Pharmaceuticals
TNXP
$205M
0

Similar funds

T. Rowe Price Associates's Q1 2022 Portfolio in Review

As of Q1 2022, T. Rowe Price Associates held 3,085 positions worth $992B, down 11% from $1.11T the previous quarter. Its ten largest holdings account for 28% of the portfolio.

T. Rowe Price Associates's Q1 2022 filing shows 108 new, 1,637 increased, 1,059 reduced and 107 closed positions. Its largest new stake was Nutrien: 6,143,560 shares worth $639M. The largest sale was Alphabet (Google) Class C, an estimated $3.24B.

By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q1 2022 buy was Nutrien: 6,143,560 shares worth $639M.
  • T. Rowe Price Associates added most to Tesla in Q1 2022, an estimated $4.45B increase.
  • T. Rowe Price Associates's biggest Q1 2022 reduction was Alphabet (Google) Class C, cutting an estimated $3.24B.
  • T. Rowe Price Associates fully exited Xilinx Inc in Q1 2022, selling an estimated $481M.
  • T. Rowe Price Associates's ten largest holdings make up 28% of its $992B portfolio in Q1 2022.
  • T. Rowe Price Associates opened 108 new positions and closed 107 in Q1 2022.
  • T. Rowe Price Associates's portfolio value fell 11% quarter-over-quarter to $992B.

Based on T. Rowe Price Associates's 13F filing for Q1 2022, filed 16 May 2022.